Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents

NCT01783730 · clinicaltrials.gov ↗
COMPLETED
Status
163
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

AbbVie